Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.25.1 (
proteasome
)
28,817
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Transcription in bovine oocytes: The goal of this study was to unravel the dynamics of transcripts thought to be critically involved in oocyte maturation. The relative abundance (RA) of DYNLL1 (cytoplasmic dynein light chain LC8),
DYNC1I1
(cytoplasmic dynein 1 intermediate chain), DCTN1 (dynactin 1; pGlued homolog, the activator of the cytoplasmic dynein complex 1), PMSB1 (
proteasome
beta subunit 1), PMSA4 (
proteasome
alfa subunit 4), PAP (poly-A polymerase) and Cx43 (connexin 43) were determined by semi-quantitative endpoint RT-PCR at different stages of IVM, that is, GV, GVBD, MI and MII in oocytes collected from follicles of two different size categories, that is, <2 mm and 2-8 mm. The RA of DYNLL1 and
DYNC1I1
were significantly higher in immature oocytes from bigger follicles than in oocytes from small follicles. Messenger RNA expression levels were similar for DCTN1, PMSB1, PMSA4, PAP, and Cx43 in the two groups during the maturation process. RA of DYNLL1,
DYNC1I1
and PMSB1 decreased significantly during IVM in oocytes from follicles 2 to 8 mm. The RA for DYNLL1 was significantly higher in GVBD and MI in the oocytes from follicles 2 to 8 mm in size compared to the other group. The higher mRNA expression of DYNLL1 and
DYNC1I1
and the diverging dynamics of DYNLL1,
DYNC1I1
, and PMSB1 mRNA expression during IVM in oocytes from the different follicle categories could be related to the developmental capacity, that is, development to blastocysts after IVF. The differences found between groups of oocytes could serve as a marker to assess the developmental capacity of bovine oocytes.
...
PMID:Effects of follicle size and stages of maturation on mRNA expression in bovine in vitro matured oocytes. 1754 84